The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma

Blood

Volumn 107, Issue 3, 2006, Pages 1174-1177

  Herranz, Michel ^b   Martín Caballero, Juan ^b   Fraga, Mario F ^b   Ruiz Cabello, Jesús ^b   Flores, Juana Maria ^b   Desco, Manuel ^b   Marquez, Victor ^b   Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; ZEBULARINE;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CAUSE OF DEATH; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; T CELL LYMPHOMA; THYMUS;

EID: 31544439102     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2033     Document Type: Article

References (24)

1. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-5440.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
3. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005;14:R65-76.
4. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457-463.
5. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol. 2005;17:55-60.
6. Hackanson B, Guo Y, Lubbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets. 2005;9:45-61.
7. Pinto A, Zagonel V, Attadia V, et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989;4:28-32.
8. Wijermans P, Lubbert M, Verhoef G, et al. Lowdose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
9. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.
10. van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004;28:785-790.
11. Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98:522-528.
12. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948-3956.
13. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7:21-29.
14. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
15. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452.
16. Zhou L, Cheng X, Connolly BA, et al. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol. 2002;321:591-599.
17. Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol. 2004;24:1270-1278.
18. Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell. 2004;6:151-158.
19. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399-409.
20. Newcomb EW, Steinberg JJ, Pellicer A. Ras oncogenes and phenotypic staging in N-methylnitrosourea- and gamma-irradiation-induced thymic lymphomas in C57BL/6J mice. Cancer Res. 1988;48:5514-5521.
21. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391-400.
22. Fraga MF, Herranz M, Espada J. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004;64:5527-5534.
23. Malumbres M, Perez de Castro I, Santos J, et al. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene. 1997;14:1361-1370.
24. Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans. 2004;32:910-912.